Actively Recruiting
Phase I Study of Safety and Pharmacokinetics of Single and Multiple Doses of PSTB100 Tablets in Healthy Adults
Led by Prospect Therapeutics (Nanjing) Limited · Updated on 2026-09-04
68
Participants Needed
1
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase I clinical trial to study PSTB100 tablets in healthy adult volunteers aged 18 to 55 years. This randomized, double-blind, placebo-controlled, dose-escalation study aims to assess the safety, tolerability, and pharmacokinetic and pharmacodynamic PKPD characteristics of PSTB100 under fasting conditions. The study includes two parts a Single Ascending Dose SAD and a Multiple Ascending Dose MAD phase, with one cohort evaluating cerebrospinal fluid CSF changes after repeated dosing. In the SAD part, participants receive a single oral dose of PSTB100 tablets in a dose-escalation design to evaluate safety and PKPD profiles. The MAD part involves multiple oral doses for seven consecutive days across three cohorts, with varying numbers of participants receiving active drug or placebo. Cohort 8 specifically includes male subjects aged 18 to 45 years and assesses CSF PKPD changes after repeated dosing. Participants will undergo various assessments including vital signs, physical exams, ECGs, laboratory tests, and blood sampling for PKPD analysis up to 72 hours post-dose in the SAD part and multiple timepoints during the MAD part. Safety and tolerability will be monitored throughout. The study also measures plasma concentration parameters such as peak levels, elimination half-life, and steady-state concentrations, along with inflammatory markers and metabolite identification. Total study duration and visit schedules vary by cohort and part.
CONDITIONS
Brief Title
PSTB100 Study in Healthy Adult Subjects
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here